Video

Dr. Cheson on the Diagnosis of Follicular Lymphoma

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.

A follicular lymphoma diagnosis often occurs incidentally, Cheson says. Too often, physicians perform a fine-needle aspiration biopsy, an inadequate way of making the diagnosis compared to an incisional or excisional biopsy. Once the diagnosis is made, patients undergo a number of staging procedures: CAT and PET scans as well as bone marrow biopsies to determine disease is in its advanced stage. Cheson says that about 80 to 90% of patients do in fact have advanced stage disease.

A physician will then assign a Follicular Lymphoma International Prognostic Index (FLIPI)‎ score by analyzing a patient's nodal areas, LDH, age, stage, and hemoglobin level to determine risk.

Related Videos
Minoo Battiwalla, MD, MS
Cynthia X. Ma, MD, PhD
Jyoti Patel, MD
Leo I. Gordon, MD
Bertram Yuh, MD, MISM, MSHCPM
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.